Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: A report of 64 patients.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of haematology"
DOI: 10.1111/bjh.18202
Abstract: Monoclonal immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) neuropathy is a rare disabling condition, most commonly treated with rituximab monotherapy (R), which leads to neurological improvement in only 30%-50% of patients. The combination of rituximab plus… read more here.
Keywords: myelin associated; ict; anti myelin; mag neuropathy ... See more keywords
Dynamic induction of the myelin‐associated growth inhibitor Nogo‐A in perilesional plasticity regions after human spinal cord injury
Sign Up to like & getrecommendations! Published in 2022 at "Brain Pathology"
DOI: 10.1111/bpa.13098
Abstract: The myelin‐associated inhibitor Nogo‐A (Reticulon 4, RTN4) restricts axonal outgrowth, plasticity, and neural circuitry formation in experimental models of spinal cord injury (SCI) and is targeted in clinical interventions starting treatment within 4 weeks post‐SCI. Specifically,… read more here.
Keywords: cord injury; myelin associated; expression; plasticity ... See more keywords
Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15553
Abstract: We evaluated the clinical and neurophysiological efficacy of rituximab (RTX) in a neurophysiologically homogeneous group of patients with monoclonal gammopathy and immunoglobulin M (IgM) anti‐myelin‐associated glycoprotein antibody (anti‐MAG) demyelinating polyneuropathy. read more here.
Keywords: demyelinating polyneuropathy; myelin associated; anti myelin; efficacy rituximab ... See more keywords